Validation of the Accuracy of DNA Fingerprinting Using Polar Bodies and Embryonic Cells


Reproductive Medicine Associates of New Jersey




DNA Fingerprinting


Other: Polar body and embryo biopsy

Study type


Funder types




Details and patient eligibility


The purpose of this study is to validate the ability to assess the genetic differences (DNA fingerprinting) on polar bodies (excess genetic material given off from the egg) and cells so that this technique may be used in the future to confirm markers of reproductive competence and improve the efficiency and safety of clinical human in vitro fertilization.

Full description

Our group has recently validated a technique involving whole genomic amplification followed by single nucleotide polymorphisms (SNP) analysis which allows DNA fingerprinting of single cells. Given that there are more than 3.3 billion base pairs that constitute the human genome, there are approximately 3 million sites where routine variation in the genetic code exists. These SNPs have been identified on average to occur approximately once every 1000 base pairs (bp) and are present on all chromosomes. 100 couples will undergo routine in vitro fertilization (IVF) stimulation, the protocol to be determined by the patient's primary doctor. Following oocyte retrieval and intracytoplasmic sperm injection (ICSI), the first polar body will be biopsied using standard laboratory procedures, and sent for genetic analysis. 24 hours later, the second polar body will be biopsied and sent for genetic analysis. Finally, the embryos will be biopsied prior to transfer and the cell will be sent for gentic analysis. Genetic results are not available prior to transfer and there are be no delays in the treatment schedule as a result of the study. Buccal swabs are collected from infants. SNP profiles are created from the polar body and embryo biopsies which are then compared to the SNP profiles created from the buccal swabs.


100 patients




21 to 43 years old


Accepts Healthy Volunteers

Inclusion and exclusion criteria

Major Inclusion: The following are major inclusion criteria:

  • Maximum of one prior failed IVF treatment cycle
  • Female partner less than 43 years of age
  • Normal day 3 FSH level (<12 mIU/mL)
  • Basal antral follicle count greater than or equal to 8
  • Ejaculated sperm specimen from the male partner with greater than 100,000 total motile
  • Donor sperm okay if patient is willing to purchase 3 extra vials for DNA testing

Exclusions: The following are exclusion criteria:

  • Diagnosis of chronic anovulation secondary to polycystic ovarian disease
  • Diagnosis of endometrial insufficiency
  • Clinical indication for PGD
  • Testicular biopsy or aspiration procedures to obtain sperm

Trial design

100 participants in 1 patient group

Study Group
Experimental group
All patients in the study receive the same treatment. All will have 2 polar body biopsies and all embryos biopsied prior to transfer.
Other: Polar body and embryo biopsy

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems